arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2007-13-3-202-207arthyper-1133Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESВлияние тиреоидного статуса и характера терапии на геометрию сердца у больных с болезнью ГрейвсаThe influence of thyrotoxicosis on the heart geometryБабенкоА. Ю.BabenkoA. Ju.noemail@neicon.ruСПбГМУ им. акад. И.П. ПавловаRussian Federation200728062007133202207Copyright © Бабенко А.Ю., 20072007Бабенко А.Ю.Babenko A.J.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1133

В настоящей статье представлены данные о влиянии тиреотоксикоза на геометрию сердца, обратимости этих изменений в зависимости от динамики уровня гормонов, характера тиреостатической терапии (мерказолил или пропицил), включения в терапию селективных или неселективных бета-адреноблокаторов. В статье также пред- ставлены сведения об уровне фактора Виллебранда у больных тиреотоксикозом и его динамике на фоне медика- ментозной терапии.

The paper is dedicated to the influence of thyrotoxicosis on the heart geometry, possibility of its reversal, depending on level of thyroid hormones, and therapy (methimasol versus propilthiouracil). Moreover, the impact of ß-blocker therapy is described. Additionally data on the level of von Willebrand factor in thyrotoxicosis and its changing depending on medical therapy and thyroid status is provided.

тиреотоксикоздилатация левого предсердиягипертрофия левого желудочкаремоделиро- вание левого желудочкамерказолилпропилтиоурацилß-адреноблокаторыReferencesWiersinga WM. Propranolol and thyroid hormone metabolism. Thyroid. 1991;1:273-7.Wiersinga WM. Propranolol and thyroid hormone metabolism. Thyroid. 1991;1:273-7.Reeves RA, From GL, Paul W, Leenen FH. Nadolol, Propranolol, and thyroid hormones: evidence membrane-stabilizing action of propranolol. Clin Pharmacol Ther. 1985;37:157-61Reeves RA, From GL, Paul W, Leenen FH. Nadolol, Propranolol, and thyroid hormones: evidence membrane-stabilizing action of propranolol. Clin Pharmacol Ther. 1985;37:157-61Leonard JL, Rosenberg IN. Subcellular distribution of thyroxine 5'-deiodinase in the rat kidney: a plasma membrane location. Endocrinology. 1978;103:274-280.Leonard JL, Rosenberg IN. Subcellular distribution of thyroxine 5'-deiodinase in the rat kidney: a plasma membrane location. Endocrinology. 1978;103:274-280.Moalic J., Bourgeois F., Mansier Р. ß1 adrenergic receptor and Gas mRNAs in rat heart as a function of mechanical load and thyroxine intoxication. Cardiovasc.Res. 27: 231-237, 1993.Moalic J., Bourgeois F., Mansier Р. ß1 adrenergic receptor and Gas mRNAs in rat heart as a function of mechanical load and thyroxine intoxication. Cardiovasc.Res. 27: 231-237, 1993.Bahouth SW, Cui X, Beauchamp MJ, Park EA. Thyroid hormone induces beta1-adrenergic receptor gene transcription through a direct repeat separated by five nucleotides. J Mol Cell Cardiol 1997;29:3223-3237.Bahouth SW, Cui X, Beauchamp MJ, Park EA. Thyroid hormone induces beta1-adrenergic receptor gene transcription through a direct repeat separated by five nucleotides. J Mol Cell Cardiol 1997;29:3223-3237.Bahouth SW. Thyroid hormones transcriptionally regulate the beta 1-adrenergic receptor gene in cultured ventricular myocytes. J Biol Chem 1991;266:15863-15869.Bahouth SW. Thyroid hormones transcriptionally regulate the beta 1-adrenergic receptor gene in cultured ventricular myocytes. J Biol Chem 1991;266:15863-15869.Klein I Thyroxine-induced cardiac hypertrophy: time course of development and inhibition by propranolol Endocrinology, 1980;123:203-210.Klein I Thyroxine-induced cardiac hypertrophy: time course of development and inhibition by propranolol Endocrinology, 1980;123:203-210.Bianco A.C, Salvatore D., Gereben B., Berry M.J. and Larsen P.R. Biochemistry, Cellular and Molecular Biology, and Physiological Roles of the Iodothyronine Selenodeiodinases Endocrine Reviews 2002, 23:38-89.Bianco A.C, Salvatore D., Gereben B., Berry M.J. and Larsen P.R. Biochemistry, Cellular and Molecular Biology, and Physiological Roles of the Iodothyronine Selenodeiodinases Endocrine Reviews 2002, 23:38-89.Rogers JS, Shane SR Factor VIII activity in normal volunteers receiving oral thyroid hormone. J Lab Clin Med 1983,102:444-449.Rogers JS, Shane SR Factor VIII activity in normal volunteers receiving oral thyroid hormone. J Lab Clin Med 1983,102:444-449.Burggraaf J, Lalezari S, Emeis JJ, аt al. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid.2001 11(2):153-160.Burggraaf J, Lalezari S, Emeis JJ, аt al. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid.2001 11(2):153-160.Napoli R, Guardasole V., Angelini V., аt al. Acute Effects of Triiodothyronine on Endothelial Function in Human Subjects J Clin Endocrinol Metab. 2006, 92:1250-1254.Napoli R, Guardasole V., Angelini V., аt al. Acute Effects of Triiodothyronine on Endothelial Function in Human Subjects J Clin Endocrinol Metab. 2006, 92:1250-1254.Horne McD.K., Singh K.K., Rosenfeld K.G. аt al Is Thyroid Hormone Suppression Therapy Prothrombotic? J. Clin. Endocrinol. & Metab. 2004; 89:4469-4473.Horne McD.K., Singh K.K., Rosenfeld K.G. аt al Is Thyroid Hormone Suppression Therapy Prothrombotic? J. Clin. Endocrinol. & Metab. 2004; 89:4469-4473.Verberne HJ, Fliers E, Prummel MF, Stam J, Brandjes DP, Wiersinga WM Thyrotoxicosis as a predisposing factor for cerebral venous thrombosis.Thyroid.2000,Jul;10(7):607-10.Verberne HJ, Fliers E, Prummel MF, Stam J, Brandjes DP, Wiersinga WM Thyrotoxicosis as a predisposing factor for cerebral venous thrombosis.Thyroid.2000,Jul;10(7):607-10.Bar Sela S, Ehrenfeld M, Eliakim M 1981 Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med 141:1191-1192Bar Sela S, Ehrenfeld M, Eliakim M 1981 Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med 141:1191-1192Hoffman, D. A. McConahey W.M., Diamond E.L. and Kurland L.T.. Mortality in women treated for hyperthyroldlsm. Am J.Epidemiol 1982 ;115:243-524.Hoffman, D. A. McConahey W.M., Diamond E.L. and Kurland L.T.. Mortality in women treated for hyperthyroldlsm. Am J.Epidemiol 1982 ;115:243-524.Flynn R.V, MacDonald T.M., Jung R.T., Morris A.D. and Leese G.P. Mortality and Vascular Outcomes in Patients Treated for Thyroid Dysfunction J. of Clinical Endocrinology & Metabolism, 2006,Vol. 91, No. 6 2159-2164.Flynn R.V, MacDonald T.M., Jung R.T., Morris A.D. and Leese G.P. Mortality and Vascular Outcomes in Patients Treated for Thyroid Dysfunction J. of Clinical Endocrinology & Metabolism, 2006,Vol. 91, No. 6 2159-2164.Osman F, Daykin J, Sheppard M, Franklyn J, Gammage M Cardiac rhythm abnormalities in thyrotoxicosis-the explanation for excess vascular mortality. J Endocrinol 2000,164:P321Osman F, Daykin J, Sheppard M, Franklyn J, Gammage M Cardiac rhythm abnormalities in thyrotoxicosis-the explanation for excess vascular mortality. J Endocrinol 2000,164:P321

The authors declare that there are no conflicts of interest present.